Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Membranous Nephropathy: early-phase trial registry
4 of 6 indexed Membranous Nephropathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Membranous Nephropathy: 6 US clinical trials tracked, 4 recruiting.
Membranous Nephropathy is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan, running 3 of these trials.
Enrollment posture brief
Registry condition membranous-nephropathy
OPEN 4 | RECR 67% | LATE 0 | EARLY 3 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Membranous Nephropathy lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Membranous Nephropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Membranous Nephropathy is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Membranous Nephropathy research.
University of Michigan accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Membranous Nephropathy enrolment sits around 150 participants.
Median target enrolment is 150 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Membranous Nephropathy splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Nephrotic Syndrome Study Network
University of Michigan
NCT01209000
NEPTUNE Match Study
University of Michigan
NCT04571658
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
University of Michigan
NCT05505500
Belimumab With Rituximab for Primary Membranous Nephropathy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03949855
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Alpine Immune Sciences
NCT05732402
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Apellis Pharmaceuticals
NCT03453619
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Membranous Nephropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Membranous Nephropathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Membranous Nephropathy page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Membranous Nephropathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Michigan sponsors the most Membranous Nephropathy trials on record, review their full trial history before evaluating a specific study. See University of Michigan's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Membranous Nephropathy condition card totals 6 registered trials; most-linked intervention APL-2; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.